Stay updated on Efficacy of EID Natalizumab in RRMS Clinical Trial
Sign up to get notified when there's something new on the Efficacy of EID Natalizumab in RRMS Clinical Trial page.

Latest updates to the Efficacy of EID Natalizumab in RRMS Clinical Trial page
- Check2 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site revision as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA sitewide NIH announcement about the terminology transition appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The clinical trial record still displays a 403 Forbidden error.SummaryDifference1%

- Check29 days agoChange DetectedThe site footer revision identifier changes from v3.7.0 to v3.7.1 while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study details, indicating restricted access to the page.SummaryDifference19%

- Check50 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0, indicating a page update rather than substantive changes to the study details.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, indicating a newer build of the page/template. This is a software/documentation update rather than a change to the study content or results.SummaryDifference0.0%

Stay in the know with updates to Efficacy of EID Natalizumab in RRMS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of EID Natalizumab in RRMS Clinical Trial page.